pregabalin

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Post-Herpetic Neuralgia

Conditions

Post-Herpetic Neuralgia

Trial Timeline

Oct 1, 2004 → Jun 1, 2006

About pregabalin

pregabalin is a approved stage product being developed by Pfizer for Post-Herpetic Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT00159666. Target conditions include Post-Herpetic Neuralgia.

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT01773993Pre-clinicalCompleted
NCT01603394ApprovedTerminated
NCT01463306Phase 3Completed
NCT01298466ApprovedWithdrawn
NCT01474772Phase 3Completed
NCT01397006ApprovedWithdrawn
NCT01020526ApprovedCompleted
NCT01202227Phase 3Completed
NCT01226667ApprovedCompleted
NCT00819988Phase 3Completed
NCT00596466Phase 3Completed
NCT00553280Phase 3Completed
NCT01061697ApprovedCompleted
NCT00891397Pre-clinicalTerminated
NCT00448916Phase 3Completed
NCT00407797ApprovedTerminated
NCT00424372Phase 3Completed
NCT00407511ApprovedCompleted
NCT00346034Phase 3Completed
NCT00843284Pre-clinicalCompleted

Competing Products

5 competing products in Post-Herpetic Neuralgia

See all competitors
ProductCompanyStageHype Score
Placebo + DS-5565Daiichi SankyoPre-clinical
26
ASP8477 + PlaceboAstellas PharmaPhase 2
35
EMA401 + PlaceboNovartisPhase 2
27
BMS-954561 + BMS-954561 + PlaceboBristol Myers SquibbPhase 2
35
HSK16149,probenecid, cimetidineHaisco Pharmaceutical GroupPhase 1
29